DBV DBV Technologies SA

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris ISIN Code: FR 0010417345

Date Total number of shares Total number of voting rights
 



 



09/30/2024



  		 



 



96,501,526



  		 



Total gross of voting rights: 96,501,526
Total net* of voting rights: 96,199,467

* Net total = total number of voting rights attached to shares – shares without voting rights

Attachment



EN
14/10/2024

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress Châtillon, France, February 25, 2025 DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the American Academy of Allergy, Asthma, and Immunology and World Allergy Organization (AAAAI/WAO) Joint Congress, February 28-March 3, 2025, in San Diego, CA. An oral abstract presentation by Dr. David Fleischer, FAAAAI, FACAAI, Profess...

February 25, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies participera au prochain congrès conjoint AAAAI/WAO

DBV Technologies participera au prochain congrès conjoint AAAAI/WAO Châtillon, France, le 25 février (22 :30 CEST) 2025 DBV Technologies participera au prochain congrès conjoint AAAAI/WAO DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), une société biopharmaceutique au stade clinique a annoncé aujourd'hui que la société participerait au congrès conjoint de l'American Academy of Allergy, Asthma, and Immunology et de la World Allergy Organization (AAAAI/WAO), qui se tiendra du 28 février au 3 mars 2025 à San Diego (Californie). David Fleischer, FAAAAI, FA...

February 25, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO ...

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF AMF Regulated InformationChâtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2024: 266,868 DBV Technologies shares,€...

January 13, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BH...

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF Informations RéglementéesChâtillon, France, le 13 janvier 2025 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), laboratoire biopharmaceutique français, publie aujourd’hui le bilan semestriel de son contrat de liquidité avec ODDO BHF. Au titre du contrat de liquidité confié à ODDO BHF, portant sur les actions de la société DBV TECHNOLOGIES, à la date du 31 décembre 2024, les moyens suivants figuraient au compte de liquidité...

January 13, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase ...

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergen...

January 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch